Mark Treherne
Cambridge Board Member
Commercial research scientist with 30 years' experience in the discovery and diagnosis of novel treatments for diseases with unmet medical need. Formerly at Pfizer and responsible for research into neurodegenerative diseases in the UK. Subsequently, set up Cambridge Drug Discovery as a co-founder and Chief Executive in 1997, which was sold to BioFocus plc in 2001 and then to Charles River.
Since then, helped to raise £300 million mostly for early-stage life sciences companies and enabled inward investment into the UK of over £6 billion. Now served on the boards of multiple therapeutics, research services and diagnostics companies worldwide. Worked with teams to out licence therapeutic assets over the last 25 years for upfront payments, milestones and future royalties exceeding £1.5 billion. More recent focus on digital biomarkers at Monument Tx and gene therapy at Spliceor, as well as near-term, revenue-generating companies, such as Talisman, Ubiquigent and NuVision.
Specialties:
• outlicensing therapeutic assets
• technical due diligence
• mergers and acquisitions
• advice on fundraising strategies
• R&D strategy and management
• outsourcing and contract pricing
• business development
• inward investment strategies
• grant appraisals and revisions